545 related articles for article (PubMed ID: 21319261)
1. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
[TBL] [Abstract][Full Text] [Related]
3. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
4. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
[TBL] [Abstract][Full Text] [Related]
5. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
7. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
[TBL] [Abstract][Full Text] [Related]
8. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.
Pekova S; Mazal O; Cmejla R; Hardekopf DW; Plachy R; Zejskova L; Haugvicova R; Jancuskova T; Karas M; Koza V; Smolej L; Bezdickova L; Kozak T
Leuk Res; 2011 Jul; 35(7):889-98. PubMed ID: 21232794
[TBL] [Abstract][Full Text] [Related]
11. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.
Pollack IF; Hamilton RL; Finkelstein SD; Campbell JW; Martinez AJ; Sherwin RN; Bozik ME; Gollin SM
Cancer Res; 1997 Jan; 57(2):304-9. PubMed ID: 9000573
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine.
Van Den Neste E; Robin V; Francart J; Hagemeijer A; Stul M; Vandenberghe P; Delannoy A; Sonet A; Deneys V; Costantini S; Ferrant A; Robert A; Michaux L
Leukemia; 2007 Aug; 21(8):1715-22. PubMed ID: 17541398
[TBL] [Abstract][Full Text] [Related]
14. A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia.
López C; Baumann T; Costa D; López-Guerra M; Navarro A; Gómez C; Arias A; Muñoz C; Rozman M; Villamor N; Colomer D; Montserrat E; Campo E; Carrió A
Br J Haematol; 2012 Mar; 156(5):612-8. PubMed ID: 22150335
[TBL] [Abstract][Full Text] [Related]
15. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
[TBL] [Abstract][Full Text] [Related]
16. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic significance of p53 and ATM gene deletion in patients with chronic lymphocytic leukemia].
Xu W; Li JY; Li L; Wu YJ; Yu H; Shen QD; Qiu HX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):450-3. PubMed ID: 19035176
[TBL] [Abstract][Full Text] [Related]
18. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
19. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
[TBL] [Abstract][Full Text] [Related]
20. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
